Enphase Energy (ENPH +2.73%) dropped more than 10% in pre-market trading, after posting a 31% fall in non-GAAP earnings per share for its fiscal first quarter, year over year (YoY). Recommended in Stock Advisor by Team Rule Breakers, the maker of solar energy technology saw U.S. revenue fall sharply – against a backdrop of tariff costs and oil-focused energy priorities. Tougher domestic trading was offset in part by international expansion.

“Europe is increasingly becoming a battery-critical market”: CEO Badrinarayanan Kothandaraman spoke of “solar and battery activations up healthy double digits across multiple European markets.” But due to competition, he said “we are reducing our distributor list prices for batteries by approximately 10% in May, which follows a 20% reduction for microinverters already implemented from December.”
Management expects $280 to $310 million revenue in Q2: Following Q1 revenue of $282.9 million, we should see non-GAAP gross margins stable between 44% and 47% – as Enphase targets commercialization of next-generation products.

Up 23% Tuesday, Kiniksa Is More Than a One-Drug Story

Tom Gardner
Team Hidden Gems

**Kiniksa **(KNSA +2.93%) is now a profitable, fast-growing biotech with a clear compounding path. ARCALYST is driving 50%+ growth w/ rising adoption, expanding prescribers, and multi-year patient use. This creates durable, recurring-like revenue. Penetration is still early, with meaningful upside as usage moves earlier in treatment. The company is reinvesting smartly. They’re driving AI-powered marketing w/ targeted outreach. This should continue to accelerate growth. Its pipeline (KPL-387, KPL-1161) is designed to extend rather than disrupt the franchise with better dosing and convenience. Lots of cash generation oncoming and a large remaining market, Kiniksa is evolving into a long-term pharma franchise. It really is not a one-drug story.

Tuesday After-Market Earnings Roundup

Booking Holdings (BKNG 3.17%) reported a 16% first-quarter revenue rise YoY, with 338 million room nights sold. Recommended by both Team Hidden Gems and Team Rule Breakers, the stock dipped 4% after hours on the back of slower growth expected in Q2 due to travel disruption from Middle East conflicts.
T-Mobile (TMUS 0.46%) ticked up 2% in pre-market trading, after mixed Q1 results saw growth in customer numbers, but a net income fall due to integration costs. Management upped its targets, and now expects 950,000 to 1.05 million new accounts for the full year. T-Mobile is a longtime SA rec by Team Rule Breakers.
Varonis (VRNS 0.52%) – recommended in SA by Team Hidden Gems – popped around 15% before the market opened. Q1 Software-as-a-Service (SaaS) revenue smashed through the company’s own expectations, with an 82% jump YoY – as total revenue grew 27%. The company lifted full-year SaaS Annual Recurring Revenue guidance, now expecting growth of 27% to 32%.

Today’s Notable Fool Favorite Results

Fiverr (FVRR 2.51%) reported a 1.6% YoY revenue dip in Q1 this morning, though it did beat management expectations. Founder and CEO Micha Kaufman spoke of “early momentum of our AI-led transformation,” as the company shifts “from a transactional marketplace to a sophisticated work platform.” The SA rec by Team Hidden Gems jumped over 10% in early trading.
EMCOR (EME 0.29%) is poised to reveal Q1 earnings before today’s opening bell, after posting a 20% YoY rise in revenue in Q4 of fiscal 2025. The stock is 54% ahead of the S&P 500 since November 2024’s SA rec by Team Hidden Gems.
eBay (EBAY +1.18%) is due to unveil Q1 figures this afternoon, after the online marketplace pioneer saw revenue jump 15% YoY in its previous quarter. The Dividend Investor rec has raised its annual dividend for 7 years in a row.

Your Take

Which two of the Magnificent Seven do you think will be the best performers over the next 5 years, and why?

Debate with friends and family, or become a member to hear what your fellow Fools are saying!

BTC-0.06%

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.